Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.

@article{Dhawan2017DifferentialTI,
  title={Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.},
  author={Mallika Sachdev Dhawan and Imke Heleen Bartelink and Rahul Aggarwal and Jim Leng and Jia-Nan Zhang and Nela Pawlowska and Manuela Terranova-Barberio and Jennifer A. Grabowsky and Andrew T. Gewitz and Amy Jo Chien and Mark M Moasser and Robin K Kelley and Tayeba Maktabi and Shaun M. Thomas and Pamela N. Munster},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2017},
  volume={23 21},
  pages={
          6400-6410
        }
}
Purpose: The PARP inhibitor (PARPi) talazoparib may potentiate activity of chemotherapy and toxicity in cells vulnerable to DNA damage.Experimental Design: This phase I study evaluated the safety, tolerability, pharmacokinetics, and efficacy of talazoparib and carboplatin. Pharmacokinetic modeling explored associations between DNA vulnerability and hematologic toxicity.Results: Twenty-four patients (eight males; 16 females) with solid tumors were enrolled in four cohorts at 0.75 and 1 mg daily… CONTINUE READING
BETA
4
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

BRCAness and prostate cancer: diagnostic and therapeutic considerations

  • Prostate Cancer and Prostatic Diseases
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Talazoparib: First Global Approval

VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 43 REFERENCES

Biological indicators of response and resistance to PARP inhibition in BRCA wild-type breast cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2015
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2012
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers